Viridian posts Q4 2025 EPS -$1.08 on $132,000 revenue, misses estimates, highlights FDA Priority Review of veligrotug
- FDA granted Priority Review to veligrotug with June 30, 2026 PDUFA date.
- Viridian reports fourth-quarter and full-year 2025 results and cash of $874.7M.
- Existing resources plus anticipated milestones and future product revenues are expected to fund its business plans through profitability.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.